IMPAX Laboratories, Inc. Confirms Patent Challenge Relating to TRICOR(R) 48mg and 145mg Tablets

HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ:IPXL) today confirms that it has initiated a challenge of the patents listed by Abbott Laboratories in connection with its TRICOR® (fenofibrate) tablets, 48 mg and 145 mg.